Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano announced today that the first patient has been dosed in a Phase 1b clinical trial evaluating Sapu003, an investigational intravenous Deciparticle(TM) formulation of everolimus. The trial targets patients with advanced mTOR-sensitive solid tumors, including HR-positive/HER2-negative breast cancer and multiple additional tumor types. This milestone marks a significant step in addressing the limitations of oral everolimus, which suffers from variable absorption and dose-limiting toxicity.
The open-label, dose-escalation study is designed to assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. Sapu003 is developed as a weekly IV formulation intended to provide more consistent drug exposure and potentially improved tolerability compared to the daily oral regimen. According to the press release, the trial will enroll patient cohorts across various solid tumor types to evaluate the drug’s potential in a broader patient population.
Oncotelic Therapeutics, a clinical-stage biopharmaceutical company, focuses on oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company’s pipeline includes innovative late-stage therapeutic candidates, supported by its proprietary AI-enabled PDAOAI platform for research and biomarker discovery. CEO Dr. Vuong Trieu has filed over 500 patent applications and holds 75 issued patents, contributing to a robust portfolio of inventions.
The implications of this trial are significant for patients with mTOR-sensitive tumors, as a more tolerable and effective formulation could improve treatment outcomes. The weekly IV dosing schedule may also enhance patient convenience and adherence. For the industry, Sapu003 represents a novel approach to reformulating an existing drug to overcome bioavailability challenges, potentially setting a precedent for other oral-to-IV conversions.
Oncotelic also holds a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates. The company’s strategic partnerships and licensing agreements further strengthen its position in oncology and rare disease therapeutics. For more details, the full press release is available at https://ibn.fm/JuGIs.
Investors can access the latest news and updates about OTLC at the company’s newsroom: https://ibn.fm/OTLC. The trial’s progression will be closely watched by the oncology community, as positive results could lead to a new standard of care for everolimus therapy.
